Print health ad spending rises in January; Novo program fights urban diabetes;

> Print health ad spending in the U.S. totaled $45 million in January, a 7% year-on-year increase. Report

> Novo Nordisk ($NVO) has launched "Cities Changing Diabetes," a partnership program to fight urban diabetes. Release

> BioAlliance Pharma has fired Oravig marketing partner Vestiq Pharmaceutical and has updated its marketing partnership for Loramyc. Release

> Stallergenes has won FDA approval for Oralair, an immunotherapy allergy tablet that will be marketed by Greer. Release

> With Sanofi Oncology's ($SNY) "Strollin' Colon" display, onlookers can walk through a giant inflatable colon and learn about the colorectal cancer screening process. More

> Johnson & Johnson Middle East ($JNJ) has teamed up with Impact BBDO Dubai to create a grandparents-only app and digital photo frame that receives and displays photos of grandchildren. More

> Specialty pharma Clinigen Group has acquired Savene, an oncology support therapy, from SpePharm AG. Release

And Finally... What is a patent troll? Congress, courts try to find out. Report

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Disorder: The Rare Disease Film Festival is back and bigger than ever, set for a West Coast debut with 50 films this fall.